Rivaroxaban Drug Profile

What is Rivaroxaban?

Rivaroxaban is a prescription anticoagulant medication that belongs to a class of drugs called direct oral anticoagulants (DOACs), also known as novel oral anticoagulants (NOACs). It is used to prevent and treat blood clots by reducing the blood’s ability to form clots. Rivaroxaban works differently from traditional blood thinners like warfarin and does not require regular blood monitoring in most cases.

Uses

Rivaroxaban is approved for several important medical conditions:

• Atrial fibrillation: Reduces stroke risk in patients with non-valvular atrial fibrillation, a heart rhythm disorder that increases clot formation risk
• Deep vein thrombosis (DVT): Treats blood clots that form in deep veins, typically in the legs
• Pulmonary embolism (PE): Treats potentially life-threatening blood clots that travel to the lungs
• Hip and knee replacement surgery: Prevents blood clots following major orthopedic surgeries
• Coronary artery disease: Used with aspirin to reduce cardiovascular events in certain patients with stable coronary artery disease or peripheral artery disease

How it works

Rivaroxaban works by directly blocking Factor Xa, a key enzyme in the blood clotting cascade that converts prothrombin to thrombin. By inhibiting Factor Xa, rivaroxaban prevents the formation of thrombin, which is essential for converting fibrinogen into fibrin, the protein that forms blood clots. This targeted approach effectively reduces the blood’s ability to form harmful clots while maintaining some clotting function for normal wound healing.

Side effects

Common side effects include:

Submit Your Paper

• Bleeding (most common and serious concern)
• Bruising easily
• Nausea
• Fatigue
• Back pain
• Muscle spasms
• Dizziness
• Anxiety

Serious side effects requiring immediate medical attention:

• Severe or uncontrolled bleeding
• Signs of internal bleeding (black stools, blood in urine, severe headache)
• Allergic reactions (rash, swelling, difficulty breathing)
• Unusual weakness or fatigue that may indicate bleeding
• Spinal or epidural hematoma (rare but serious bleeding around the spine)

Warnings and precautions

• Bleeding risk: Patients with active bleeding, bleeding disorders, or recent surgery should avoid rivaroxaban or use with extreme caution
• Kidney function: Dose adjustments or avoidance may be necessary in patients with severe kidney disease, as the drug is partially eliminated through the kidneys
• Pregnancy and breastfeeding: Not recommended during pregnancy due to potential bleeding risks to both mother and fetus; safety during breastfeeding is not established
• Surgery and procedures: Must be discontinued before elective surgery or invasive procedures to reduce bleeding risk, with timing dependent on kidney function and bleeding risk
• Liver disease: Should be avoided in patients with severe liver disease or liver disease associated with blood clotting problems

Interactions

Several medications and substances can significantly interact with rivaroxaban:

• Strong CYP3A4 inhibitors (ketoconazole, ritonavir): Increase rivaroxaban levels, raising bleeding risk
• Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine): Decrease rivaroxaban effectiveness
• Other anticoagulants (warfarin, heparin): Significantly increase bleeding risk when used together
• Antiplatelet drugs (aspirin, clopidogrel): Increase bleeding risk, though some combinations are therapeutically used under careful monitoring
• NSAIDs (ibuprofen, naproxen): May increase bleeding risk
• St. John’s wort: May reduce rivaroxaban effectiveness
• Combined P-gp and strong CYP3A4 inhibitors: Can significantly increase drug levels

Check interactions with the GMJ Interaction Checker

Dosage

Rivaroxaban dosing varies significantly based on the condition being treated and patient factors. For atrial fibrillation, the typical dose is 20 mg once daily with the evening meal for patients with normal kidney function. For DVT and PE treatment, dosing often starts at 15 mg twice daily for the first 21 days, followed by 20 mg once daily. Post-surgical prevention typically uses 10 mg once daily. Doses must be adjusted for kidney function, and patients with moderate to severe kidney impairment require careful dose reduction. All dosing decisions should be made by a healthcare provider based on individual patient factors, kidney function, bleeding risk, and the specific condition being treated.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).